ZA200601140B - Aminopyridine-derivatives as inductible no-synthase inhibitors - Google Patents

Aminopyridine-derivatives as inductible no-synthase inhibitors Download PDF

Info

Publication number
ZA200601140B
ZA200601140B ZA200601140A ZA200601140A ZA200601140B ZA 200601140 B ZA200601140 B ZA 200601140B ZA 200601140 A ZA200601140 A ZA 200601140A ZA 200601140 A ZA200601140 A ZA 200601140A ZA 200601140 B ZA200601140 B ZA 200601140B
Authority
ZA
South Africa
Prior art keywords
phenyl
compounds
imidazo
alkyl
alkoxy
Prior art date
Application number
ZA200601140A
Other languages
English (en)
Inventor
Boer Rainer
Marx Degenhard
Ulrich Wolf-Ruediger
Eltze Manfrid
Ruediger Nave
Strub Andreas
Graedler Ulrich
Fuchss Thomas
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of ZA200601140B publication Critical patent/ZA200601140B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200601140A 2003-10-01 2006-02-08 Aminopyridine-derivatives as inductible no-synthase inhibitors ZA200601140B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03022040 2003-10-01

Publications (1)

Publication Number Publication Date
ZA200601140B true ZA200601140B (en) 2007-05-30

Family

ID=34707254

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200601140A ZA200601140B (en) 2003-10-01 2006-02-08 Aminopyridine-derivatives as inductible no-synthase inhibitors

Country Status (16)

Country Link
US (3) US7317021B2 (enExample)
EP (1) EP1670798A1 (enExample)
JP (1) JP2007507464A (enExample)
KR (1) KR20060092219A (enExample)
CN (1) CN100415746C (enExample)
AU (1) AU2004303515A1 (enExample)
BR (1) BRPI0415034A (enExample)
CA (1) CA2540230A1 (enExample)
EA (1) EA200600601A1 (enExample)
IL (1) IL173628A0 (enExample)
MX (1) MXPA06003345A (enExample)
NO (1) NO20061789L (enExample)
NZ (1) NZ546394A (enExample)
RS (1) RS20060206A (enExample)
WO (1) WO2005061496A1 (enExample)
ZA (1) ZA200601140B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003351A (es) 2003-10-01 2006-06-08 Altana Pharma Ag Derivados de imidazopiridina como inhibidores de no-sintasa inducible.
KR20060092220A (ko) 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타아제 저해제로서의 이미다조피리딘 유도체
KR20060092221A (ko) 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타제 억제제로서의이미다조（4,5-ｂ）피리딘 유도체
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006103255A1 (en) 2005-03-31 2006-10-05 Nycomed Gmbh Imidazopyridine derivatives useful as inos inhibitors
AU2008271170A1 (en) * 2007-06-27 2009-01-08 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
US20100278751A1 (en) * 2009-04-30 2010-11-04 Washington University Radiolabeled 2-amino-4-alkyl-6-(haloalkyl)pyridine compounds and their use in diagnostic imaging
CA2800618C (en) 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
CN117215117A (zh) 2017-05-15 2023-12-12 索尼公司 照明单元和显示设备
US12240815B2 (en) * 2020-02-24 2025-03-04 Northwestern University Potent and selective human neuronal nitric oxide synthase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045564A (en) * 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
SE418966B (sv) 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
ATE384722T1 (de) * 2002-03-27 2008-02-15 Nycomed Gmbh Alkoxypyridinderivate
MXPA06003351A (es) 2003-10-01 2006-06-08 Altana Pharma Ag Derivados de imidazopiridina como inhibidores de no-sintasa inducible.
KR20060092220A (ko) 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타아제 저해제로서의 이미다조피리딘 유도체
KR20060092221A (ko) 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타제 억제제로서의이미다조（4,5-ｂ）피리딘 유도체
BRPI0414873A (pt) 2003-10-01 2006-12-12 Altana Pharma Ag derivados de imidazopiridina como inibidores de no-sintase induzìveis

Also Published As

Publication number Publication date
MXPA06003345A (es) 2006-06-08
US20100280002A1 (en) 2010-11-04
JP2007507464A (ja) 2007-03-29
US20070043072A1 (en) 2007-02-22
AU2004303515A1 (en) 2005-07-07
HK1096968A1 (zh) 2007-06-15
US7781453B2 (en) 2010-08-24
US20080176894A1 (en) 2008-07-24
IL173628A0 (en) 2006-07-05
CN100415746C (zh) 2008-09-03
US7317021B2 (en) 2008-01-08
WO2005061496A8 (en) 2006-02-16
WO2005061496A1 (en) 2005-07-07
CN1856493A (zh) 2006-11-01
EA200600601A1 (ru) 2006-10-27
CA2540230A1 (en) 2005-07-07
NO20061789L (no) 2006-04-24
NZ546394A (en) 2009-08-28
RS20060206A (sr) 2008-08-07
EP1670798A1 (en) 2006-06-21
BRPI0415034A (pt) 2006-12-12
KR20060092219A (ko) 2006-08-22

Similar Documents

Publication Publication Date Title
EP1254138B1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US8513277B2 (en) Pyrrolo[3,2-C] pyridine derivatives and processes for the preparation thereof
NO316564B1 (no) Fremgangsmåte til fremstilling av imidazokinolinaminer
ZA200601140B (en) Aminopyridine-derivatives as inductible no-synthase inhibitors
ZA200407766B (en) Novel alkoxypyridine-derivatives
EP1879893B1 (en) Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
EP0554098B1 (en) Process for the preparation of imidazo(4,5-b)pyridine derivatives
US20050014780A1 (en) Process for preparing 5-sulfonamido-8-hydroxy-1,6-naphthyridine-7-carboxamides
EP1461338B1 (en) Improved process for the preparation of 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one
TW201035094A (en) 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
KR101657599B1 (ko) 피롤로[2,3-c]피리딘 유도체 또는 이의 약학적으로 허용가능한 염의 제조방법
EP1286993B1 (en) Imidazopyridin-8-ones
US20070249658A1 (en) Pyrrolo[3,2-C]Pyridine Deriatives and Processes for the Preparation Thereof
EP1526135A1 (en) Azabenzodiazepines as pde4 inhibitors
HK1052500B (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
CZ291419B6 (cs) Deriváty pyridinu